651
|
Wang S, Ou W, Sun H, Yang H, Ye X, Fang Q. Adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.7563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7563 Background: We evaluate effect of postoperative adjuvant chemotherapy on overall survival after complete resection of stage III-N2 non-small-cell lung cancer. Methods: From Jan.1999 to Dec. 2003, a total of 150 stage III-N2 non-small cell lung cancer patients randomly received four cycles of chemotherapy (NVB25mg/m2, D1,D5 or paclitaxel 175mg/m2, D1 / carboplatin AUC=5, D1) or observation after operation. Results: The median survival for the 150 patients was 879 days, with a 1-year survival rate of 81%, 3-year survival rate of 43%, and 5-year survival rate of 28%.There was significant difference in median survival between chemotherapy and control group (897 days vs 821 days p=0.04), and also there was significant difference in 5-year survival rate (30% vs 24% p<0.05). The most common site of recurrence was brain. 26% (39/150) of patients recurred in the brain as their first site, 22% (18/79) for chemotherapy group, 29% (21/71) for control group. The median survival time for brain metastasis patients between chemotherapy and control group is no difference (812 days vs 512 days, p=0.122), but there was significant difference in 2-year survival rate (66.71% vs 37.6% p<0.05). Conclusions: Postoperative adjuvant chemotherapy dose significantly improves median survival among completely resected stage III-N2 non-small-cell lung cancer patients, and significantly improves 5-year survival rate. It dose not decrease incidence of brain metastasis but postpone the time of brain metastasis in chemotherapy group. No significant financial relationships to disclose.
Collapse
|
652
|
Wang JZ, An TT, Yang L, Bai H, Zhao J, Duan JC, Li PP, Wu MN, Sun H, Yang P, Wang JZ. Effects of immediate compared with delayed gefitinib after front-line chemotherapy in Chinese with advanced non-small cell lung cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8069 Background: To compare therapeutic effects of immediate vs. delayed gefitinib used for advanced non-small cell lung cancer (NSCLC) patients who obtained disease control (DC) after front-line chemotherapy in Chinese population. Methods: The study included 121 Chinese with advanced NSCLC treated with standard chemotherapy and obtained DC followed by either immediate gefitinib (66 cases) or delayed gefitinib, i.e. when tumors progressed (55 cases). The disease control rate (DCR), median progression-free survival time (PFS), median overall survival time (OS) of the two groups were analyzed. The impact of EGFR mutation status on the treatments was also evaluated. Results: The median PFS of patients treated in the immediate treatment setting was significantly longer than that of patients without gefitinib treatment (15.23 months versus 8.13 months,P<0.001). However, the overall median PFS was similar in patients treated with either immediate or delayed settings (15.23 months and 16.23 months respectively, P=0.450). There was no significant difference in OS between the two groups. Although patients whose tumors had EGFR mutation showed a longer median PFS compared to those without the mutation in both treatment groups, similar overall PFS was observed between the groups for patients with EGFR mutation (18.75 months and 18.30 months for maintenance and second-line groups, respectively). Conclusions: Immediate gefitinib use may improve PFS for Chinese patients with advanced NSCLC after front-line chemotherapy. However, similar PFS may be achieved by delayed use of gefitinib. No significant financial relationships to disclose.
Collapse
|
653
|
Wang C, Xie X, You C, Zhang C, Cheng M, He M, Sun H, Mao B. Placement of covered stents for the treatment of direct carotid cavernous fistulas. AJNR Am J Neuroradiol 2009; 30:1342-6. [PMID: 19342540 DOI: 10.3174/ajnr.a1583] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND AND PURPOSE Endovascular detachable balloon occlusion and coil occlusion are 2 well-established options for the treatment of direct carotid cavernous fistulas (DCCFs). In recent years, covered stents have been applied in the treatment of neurovascular pathologies such as aneurysms, pseudoaneurysms, arterial dissections, and DCCFs. The purpose of this study was to investigate the clinical efficacy of covered stents for the treatment of DCCFs. MATERIALS AND METHODS Ten consecutive patients underwent covered-stent placement after failure of detachable balloon occlusion for the treatment of their DCCFs. Clinical and angiographic follow-up ranged from 5 to 48 months (mean, 18.2 months) after stent placement. RESULTS Stent placement was technically successful in all except 1 patient. In this patient, stent placement failed after multiple attempts because of rigidity of the Jostent GraftMaster Coronary Stent Graft and the tortuous anatomy of the internal carotid artery (ICA). Complete exclusion of the fistula was achieved in 6 patients immediately after stent deployment. Endoleak was observed in 3 patients. Re-dilation of the stent avoided the endoleak in 2 patients; in 1 of these 2 patients, formerly improved symptoms recurred the next morning and the ipsilateral ICA was occluded with detachable balloons. Spasm of the ICA was observed in most of the patients after stent placement; however, angioplasty was not required. Symptoms improved in all patients after treatment, without thromboembolic events. Follow-up cerebral angiography showed complete exclusion of all DCCFs and stent patency without intrastent stenosis in the 8 patients who had successful deployment of the stent. CONCLUSIONS Although a larger sample and expanded follow-up are needed, our series shows that covered stents can be used in the treatment of DCCFs with symptomatic relief.
Collapse
|
654
|
Sun H, Sun L, Li Y, Shao M, Cheng X, Ge N, Lu J, Li S. ACE-inhibitor Suppresses the Apoptosis Induced by Endoplasmic Reticulum Stress in Renal Tubular in Experimental Diabetic Rats. Exp Clin Endocrinol Diabetes 2009; 117:336-44. [DOI: 10.1055/s-0028-1112148] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
655
|
Suzuki M, Zheng X, Zhang X, Ichim TE, Sun H, Kubo N, Beduhn M, Shunnar A, Garcia B, Min WP. Inhibition of allergic responses by CD40 gene silencing. Allergy 2009; 64:387-97. [PMID: 19175598 DOI: 10.1111/j.1398-9995.2008.01839.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Gene silencing using small interfering RNA (siRNA) is a potent method of specifically knocking down molecular targets. Small interfering RNA is therapeutically promising, however, treatment of allergic diseases with siRNA has not been explored in vivo. The aim of this study was to evaluate therapeutic effects of CD40 siRNA on inhibition of allergic responses. METHODS Mice sensitized with ovalbumin (OVA) and alum were treated with CD40 siRNA, scrambled siRNA, or phosphate buffer saline (PBS) alone, and then challenged intranasally with OVA. RESULTS A significant reduction in nasal allergic symptoms was observed in the CD40 siRNA treated OVA-allergic mice compared to the controls of scrambled siRNA and PBS alone, which is correlated with the decrease of local eosinophil accumulation. CD40 siRNA treatment knocked down CD40 expression on dendritic cells (DCs) in vivo and impaired their antigen presenting function. Treatment with CD40 siRNA resulted in inhibition of OVA-specific T cell response and decrease of interleukin-4 (IL-4), IL-5, and interferon-gamma production from T cells stimulated with OVA. Administration of CD40 siRNA also suppressed CD40 expression on B cells, resulting in down-regulation of OVA-specific immunoglobulin E (IgE), IgG1, and IgG2a levels. Additionally, increased regulatory T cells were observed in the CD40 siRNA treated mice. CONCLUSIONS The present study demonstrates a novel therapeutic use for siRNA in allergy. CD40 siRNA attenuated allergy through inhibition of DC and B cell functions and generation of regulatory T (Treg) cells.
Collapse
|
656
|
Sun H, McLane M, Vonakis B. Role of Lyn Kinase in Leukotriene C4 (LTC4) Secretion from Mast Cells upon High Affinity IgE Receptor (FceRI) Stimulation. J Allergy Clin Immunol 2009. [DOI: 10.1016/j.jaci.2008.12.439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
657
|
Aaltonen T, Adelman J, Akimoto T, Albrow MG, Alvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Aoki M, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Azzi-Bacchetta P, Azzurri P, Bacchetta N, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Baroiant S, Bar-Shalom S, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Bednar P, Behari S, Bellettini G, Bellinger J, Belloni A, Benjamin D, Beretvas A, Beringer J, Berry T, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bolshov A, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canelli F, Canepa A, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cooper B, Copic K, Cordelli M, Cortiana G, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lentdecker G, De Lorenzo G, Dell'orso M, Demortier L, Deng J, Deninno M, De Pedis D, Derwent PF, Di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Forrester S, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Genser K, Gerberich H, Gerdes D, Giagu S, Giakoumopolou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Han JY, Handler R, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hauser J, Hays C, Heck M, Heijboer A, Heinemann B, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, Iyutin B, James E, Jayatilaka B, Jeans D, Jeon EJ, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Klute M, Knuteson B, Ko BR, Koay SA, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kraus J, Kreps M, Kroll J, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhlmann SE, Kuhr T, Kulkarni NP, Kusakabe Y, Kwang S, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, Lecompte T, Lee J, Lee J, Lee YJ, Lee SW, Lefèvre R, Leonardo N, Leone S, Levy S, Lewis JD, Lin C, Lin CS, Linacre J, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lu RS, Lucchesi D, Lueck J, Luci C, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Lytken E, Mack P, Macqueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin M, Martin V, Martínez M, Martínez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miles J, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello M, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Neu C, Neubauer MS, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oh SH, Oh YD, Oksuzian I, Okusawa T, Oldeman R, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pinera L, Pitts K, Plager C, Pondrom L, Portell X, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Punzi G, Pursley J, Rademacker J, Rahaman A, Rajaraman A, Ramakrishnan V, Ranjan N, Redondo I, Reisert B, Rekovic V, Renton P, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Saarikko H, Safonov A, Sakumoto WK, Salamanna G, Saltó O, Santi L, Sarkar S, Sartori L, Sato K, Savoy-Navarro A, Scheidle T, Schlabach P, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scott AL, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sfyria A, Shalhout SZ, Shapiro MD, Shears T, Shepard PF, Sherman D, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soderberg M, Soha A, Somalwar S, Sorin V, Spalding J, Spinella F, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Stuart D, Suh JS, Sukhanov A, Sun H, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Tourneur S, Trischuk W, Tu Y, Turini N, Ukegawa F, Uozumi S, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Veszpremi V, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Würthwein F, Wagner P, Wagner RG, Wagner RL, Wagner-Kuhr J, Wagner W, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Wester WC, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wynne SM, Yagil A, Yamamoto K, Yamaoka J, Yamashita T, Yang C, Yang UK, Yang YC, Yao WM, Yeh GP, Yoh J, Yorita K, Yoshida T, Yu GB, Yu F, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zaw I, Zhang X, Zheng Y, Zucchelli S. Search for maximal flavor violating scalars in same-charge lepton pairs in pp collisions at sqrt[s]=1.96 TeV. PHYSICAL REVIEW LETTERS 2009; 102:041801. [PMID: 19257412 DOI: 10.1103/physrevlett.102.041801] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2008] [Indexed: 05/27/2023]
Abstract
Models of maximal flavor violation (MxFV) in elementary particle physics may contain at least one new scalar SU(2) doublet field Phi(FV)=(eta(0),eta(+)) that couples the first and third generation quarks (q_(1), q_(3)) via a Lagrangian term L(FV)=xi(13)Phi(FV)q(1)q(3). These models have a distinctive signature of same-charge top-quark pairs and evade flavor-changing limits from meson mixing measurements. Data corresponding to 2 fb(-1) collected by the Collider Dectector at Fermilab II detector in pp[over ] collisions at sqrt[s]=1.96 TeV are analyzed for evidence of the MxFV signature. For a neutral scalar eta(0) with m_(eta;(0))=200 GeV/c(2) and coupling xi(13)=1, approximately 11 signal events are expected over a background of 2.1+/-1.8 events. Three events are observed in the data, consistent with background expectations, and limits are set on the coupling xi(13) for m(eta(0)=180-300 GeV/c(2).
Collapse
|
658
|
Li D, Sun H, Levesque P. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety. Cardiovasc Hematol Agents Med Chem 2009; 7:64-75. [PMID: 19149545 DOI: 10.2174/187152509787047621] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Atrial fibrillation (AF) is a highly prevalent arrhythmia and responsible for significant morbidity, mortality and health care cost. The prevalence of AF is expected to increase markedly with the aging population. The use of conventional antiarrhythmic agents has been limited by potentially fatal ventricular proarrhythmia. Rhythm control could become the preferred treatment strategy for AF if antiarrhythmic agents that are similarly or more effective, but safer, than currently approved AF agents become available. A subanalysis of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) trial data showed that normal sinus rhythm confers a survival benefit in AF, suggesting that rhythm control, if achieved without the adverse effects related to current antiarrhythmic medications, may offer a significant survival advantage over rate control. Considerable work has been performed to explore novel, potentially safer antiarrhythmic drug targets for AF therapy, and some of these drug targets are currently being tested in experimental and clinical proof of concept studies. This article summarizes relevant aspects of the cellular electrophysiology of AF and reviews the actions of pharmacological agents being considered for the prevention and treatment of AF, focusing on atrial selective antiarrhythmic agents. A variety of drugs that inhibit the atrium-specific ultra rapid delayed rectifier potassium current (IKur) are being evaluated pre-clinically, but human experience with these agents is limited. The acetylcholine-activated current (IKACh) is another novel candidate target for atrial-specific drug therapy. The constitutively active form of this current is increased in human AF and pharmacological inhibition might be of therapeutic value. Certain drugs have IKACh blocking properties, but similar to IKur-blockers, none have been shown to have pure selectivity for this current. Newer agents being studied also include gap junction modulators and angiotensin-converting enzyme inhibitors. There is great hope that at least some of these agents will ultimately be available for effective and safer clinical treatment and prevention of AF.
Collapse
|
659
|
Balabanova IM, Fedorin IM, Malomanova NA, Drobnievskiĭ F, Nikolaevskiĭ VV, Sun H, Mashkova IA, Simak TG, Kontsevaia IS, Ignat'eva OA, Mironova SA. [Use of automated bactec MGIT 960 system in the diagnosis of resistance to reserve drugs agents in Samara]. TUBERKULEZ I BOLEZNI LEGKIKH 2009:63-70. [PMID: 20000083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The paper gives the results of a demonstration project to introduce a test for drug sensitivity to second-line antituberculous agents for patients with multidrug-resistant (MDR) tuberculosis at a routine large Russian laboratory. Two hundred and thirty MDR isolates were examined; of them 8.7% had extreme drug resistance. The cost of this test was estimated to be US $ 33.4. The introduction of this test is possible and essential for the precise and timely choice of antituberculous therapy for patients with MDR tuberculosis.
Collapse
|
660
|
Sun H, Choy T, Zhu D, Yam W, Fung Y. Nano-silver-modified PQC/DNA biosensor for detecting E. coli in environmental water. Biosens Bioelectron 2009; 24:1405-10. [DOI: 10.1016/j.bios.2008.08.008] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2008] [Revised: 07/24/2008] [Accepted: 08/05/2008] [Indexed: 02/07/2023]
|
661
|
Li M, Yang LJ, Zhu XH, Zhang YS, Sun H, Jiang PD, Zhang RR, Tang W, Cai Y. The Leser-Trélat sign is associated with nasopharyngeal carcinoma: case report and review of cases reported in China. Clin Exp Dermatol 2008; 34:52-4. [PMID: 19076792 DOI: 10.1111/j.1365-2230.2008.02923.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The sign of Leser-Trélat (LT) is defined as the sudden eruption of multiple seborrhoeic keratoses (SKs), or increase in the number and size of existing SKs, associated with an underlying malignancy. A 75-year-old man was admitted to our hospital with dyspnoea and multiple verrucous papules that had been developing gradually over the previous 30 years. During the 3 months before presentation, the number of SKs on his chest and back had increased rapidly. A diagnosis of nasopharyngeal carcinoma was made based on results of computed tomography, endoscopy and biopsy examinations. The patient is receiving radiotherapy at present. To our knowledge, this is the first case of the Leser-Trélat sign associated with nasopharyngeal carcinoma.
Collapse
|
662
|
Lv H, Sun H, Sun W, Liu L, Wang P, Wang X, Cao H. Pharmacokinetic studies of a Chinese triple herbal drug formula. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2008; 15:993-1001. [PMID: 18339526 DOI: 10.1016/j.phymed.2008.01.006] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2007] [Revised: 10/11/2007] [Accepted: 01/18/2008] [Indexed: 05/26/2023]
Abstract
Yin Chen Hao Tang preparation (YCHTP) is a classic traditional Chinese medicine formula, which is commonly used for clinical treatment of hepatological diseases. In this study, a rapid and validated high-performance liquid chromatography (HPLC) method was developed to simultaneously identify 6,7-dimethylesculetin and geniposide in rat plasma. This assay was performed on a Dikma Diamonsil RP(18) column (200 mm×4.6 mm, 5 μm) with acetonitrile-methanol-water (0.1% formic acid) as the mobile phase, showing acceptable linearity, intra- and inter-day precision and accuracy (R.S.D.=5%), and absolute recovery for two analytes (74%); the limits of quantitation were 0.4 and 1.12 μg/ml, and the limits of detection were 0.06 and 0.09 μg/ml for two analytes. The developed method was successfully applied to study the effect of formula compatibility on the pharmacokinetics of 6,7-dimethylesculetin and geniposide in YCHTP when orally administrating an effective human daily dose of YCHTP to rats. We surmise that formula compatibility can significantly influence the pharmacokinetics of YCHTP, and we have elucidated and validated the compatible administration of YCHTP.
Collapse
|
663
|
Sun H, Lu J, Bai L, Nikolovska-Coleska Z, Yang C, Qiu S, Ling X, Guo M, Yang D, Wang S. 129 POSTER Design, synthesis and evaluation of bivalent conformationally constrained Smac mimetics as a new class of anticancer agents. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72061-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
664
|
Wang W, Cheng Y, Deevi D, Li H, Prewett M, Bassi R, Malabunga M, Paz K, Sun H, Tonra J. 200 POSTER Transcriptome analysis method for in vivo mechanism of action study: IMC-D11 anti-FGFR3 +/− cisplatin in bladder cancer models. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)72132-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
665
|
Jones CD, Sun H, Ette EI. Designing Cross-Sectional Population Pharmacokinetic Studies: Implications for Pediatric and Animal Studies. ACTA ACUST UNITED AC 2008. [DOI: 10.3109/10601339609035949] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
666
|
Aaltonen T, Adelman J, Akimoto T, Albrow MG, Alvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Aoki M, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Azzi-Bacchetta P, Azzurri P, Bacchetta N, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Baroiant S, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Bednar P, Behari S, Bellettini G, Bellinger J, Belloni A, Benjamin D, Beretvas A, Beringer J, Berry T, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bolshov A, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canelli F, Canepa A, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cooper B, Copic K, Cordelli M, Cortiana G, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lentdecker G, De Lorenzo G, Dell'Orso M, Demortier L, Deng J, Deninno M, De Pedis D, Derwent PF, Di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Forrester S, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Genser K, Gerberich H, Gerdes D, Giagu S, Giakoumopolou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Han JY, Handler R, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hauser J, Hays C, Heck M, Heijboer A, Heinemann B, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, Iyutin B, James E, Jayatilaka B, Jeans D, Jeon EJ, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Klute M, Knuteson B, Ko BR, Koay SA, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kraus J, Kreps M, Kroll J, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhlmann SE, Kuhr T, Kulkarni NP, Kusakabe Y, Kwang S, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, LeCompte T, Lee J, Lee J, Lee YJ, Lee SW, Lefèvre R, Leonardo N, Leone S, Levy S, Lewis JD, Lin C, Lin CS, Linacre J, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lu RS, Lucchesi D, Lueck J, Luci C, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Lytken E, Mack P, MacQueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin M, Martin V, Martínez M, Martínez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miles J, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello M, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Neu C, Neubauer MS, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oh SH, Oh YD, Oksuzian I, Okusawa T, Oldeman R, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pinera L, Pitts K, Plager C, Pondrom L, Portell X, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Reisert B, Rekovic V, Renton P, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Saarikko H, Safonov A, Sakumoto WK, Salamanna G, Saltó O, Santi L, Sarkar S, Sartori L, Sato K, Savoy-Navarro A, Scheidle T, Schlabach P, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scott AL, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sfyrla A, Shalhout SZ, Shapiro MD, Shears T, Shepard PF, Sherman D, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soderberg M, Soha A, Somalwar S, Sorin V, Spalding J, Spinella F, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Stuart D, Suh JS, Sukhanov A, Sun H, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Tourneur S, Trischuk W, Tu Y, Turini N, Ukegawa F, Uozumi S, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Veszpremi V, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Würthwein F, Wagner P, Wagner RG, Wagner RL, Wagner-Kuhr J, Wagner W, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Wester WC, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wynne SM, Yagil A, Yamamoto K, Yamaoka J, Yamashita T, Yang C, Yang UK, Yang YC, Yao WM, Yeh GP, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zaw I, Zhang X, Zheng Y, Zucchelli S. Search for doubly charged Higgs bosons with lepton-flavor-violating decays involving tau leptons. PHYSICAL REVIEW LETTERS 2008; 101:121801. [PMID: 18851361 DOI: 10.1103/physrevlett.101.121801] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2007] [Indexed: 05/26/2023]
Abstract
We search for pair production of doubly charged Higgs particles (H+/- +/-) followed by decays into electron-tau (etau) and muon-tau (mutau) pairs using data (350 pb(-1) collected from [over]pp collisions at sqrt[s]=1.96 TeV by the CDF II experiment. We search separately for cases where three or four final-state leptons are detected, and combine results for exclusive decays to left-handed etau (mutau) pairs. We set an H+/- +/- lower mass limit of 114(112) GeV/c(2) at the 95% confidence level.
Collapse
|
667
|
Bao J, Tu Z, Wang J, Ye F, Sun H, Qin M, Shi Y, Bu H, Li Y. A Novel Accurate Rapid ELISA for Detection of Urinary Connective Tissue Growth Factor, a Biomarker of Chronic Allograft Nephropathy. Transplant Proc 2008; 40:2361-4. [DOI: 10.1016/j.transproceed.2008.07.122] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
668
|
Li B, Yan J, Zhou T, Wang Z, Li H, Sun H. A Phase I Study of Concurrent Late Course Accelerated Hyper-fractionated Radiotherapy and Capecitabine and Cisplatin for Local Advanced Esophageal Cancer. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.1744] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
669
|
Pavone M, Bulun S, Sun H, Reierstad S, Innes J, Cheng Y. Progesterone-dependent induction of STRA6 regulates retinoic acid action in the endometrium. Fertil Steril 2008. [DOI: 10.1016/j.fertnstert.2008.07.372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
670
|
Zhao Z, Li B, Yin Y, Wang Z, Fu Z, Fang S, Liu T, Sun H. Study on Different SPECT/CT Image Registration Methods using Motion-phantom. Int J Radiat Oncol Biol Phys 2008. [DOI: 10.1016/j.ijrobp.2008.06.285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
671
|
Aaltonen T, Adelman J, Akimoto T, Albrow MG, Alvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Aoki M, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Azzi-Bacchetta P, Azzurri P, Bacchetta N, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Baroiant S, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Bednar P, Behari S, Bellettini G, Bellinger J, Belloni A, Benjamin D, Beretvas A, Beringer J, Berry T, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bolshov A, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canelli F, Canepa A, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cooper B, Copic K, Cordelli M, Cortiana G, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lentdecker G, De Lorenzo G, Dell'Orso M, Demortier L, Deng J, Deninno M, De Pedis D, Derwent PF, Di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Forrester S, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Genser K, Gerberich H, Gerdes D, Giagu S, Giakoumopolou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Han JY, Handler R, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hauser J, Hays C, Heck M, Heijboer A, Heinemann B, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, Iyutin B, James E, Jayatilaka B, Jeans D, Jeon EJ, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Klute M, Knuteson B, Ko BR, Koay SA, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kraus J, Kreps M, Kroll J, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhlmann SE, Kuhr T, Kulkarni NP, Kusakabe Y, Kwang S, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, LeCompte T, Lee J, Lee J, Lee YJ, Lee SW, Lefèvre R, Leonardo N, Leone S, Levy S, Lewis JD, Lin C, Lin CS, Linacre J, Lindgren M, Lipeles E, Liss TM, Lister A, Litvintsev DO, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lu RS, Lucchesi D, Lueck J, Luci C, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Lytken E, Mack P, MacQueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin M, Martin V, Martínez M, Martínez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miles J, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello M, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Neu C, Neubauer MS, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oh SH, Oh YD, Oksuzian I, Okusawa T, Oldeman R, Orava R, Osterberg K, Griso SP, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pinera L, Pitts K, Plager C, Pondrom L, Portell X, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Reisert B, Rekovic V, Renton P, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Saarikko H, Safonov A, Sakumoto WK, Salamanna G, Saltó O, Santi L, Sarkar S, Sartori L, Sato K, Savoy-Navarro A, Scheidle T, Schlabach P, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scott AL, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sfyrla A, Shalhout SZ, Shapiro MD, Shears T, Shepard PF, Sherman D, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soderberg M, Soha A, Somalwar S, Sorin V, Spalding J, Spinella F, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Stuart D, Suh JS, Sukhanov A, Sun H, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Tourneur S, Trischuk W, Tu Y, Turini N, Ukegawa F, Uozumi S, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Veszpremi V, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Würthwein F, Wagner P, Wagner RG, Wagner RL, Wagner-Kuhr J, Wagner W, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Wester WC, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wynne SM, Yagil A, Yamamoto K, Yamaoka J, Yamashita T, Yang C, Yang UK, Yang YC, Yao WM, Yeh GP, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zaw I, Zhang X, Zheng Y, Zucchelli S. Search for pair production of scalar top quarks decaying to a tau lepton and a b quark in pp over collisions at sqrt s=1.96 TeV. PHYSICAL REVIEW LETTERS 2008; 101:071802. [PMID: 18764522 DOI: 10.1103/physrevlett.101.071802] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2008] [Indexed: 05/26/2023]
Abstract
We search for pair production of supersymmetric top quarks (t over1), followed by R-parity violating decay t over1-->taub with a branching ratio beta, using 322 pb(-1) of pp over collisions at sqrt s=1.96 TeV collected by the upgraded Collider Detector at Fermilab. Two candidate events pass our final selection criteria, consistent with the standard model expectation. We set upper limits on the cross section sigma(t over1t over1) x beta2 as a function of the top-squark mass m(t over1). Assuming beta=1, we set a 95% confidence level limit m(t over1)>153 GeV/c2. The limits are also applicable to the case of a third-generation scalar leptoquark (LQ3) decaying LQ3-->taub.
Collapse
|
672
|
Baumbusch LO, Aarøe J, Johansen FE, Hicks J, Sun H, Bruhn L, Gunderson K, Naume B, Kristensen VN, Liestøl K, Børresen-Dale AL, Lingjaerde OC. Comparison of the Agilent, ROMA/NimbleGen and Illumina platforms for classification of copy number alterations in human breast tumors. BMC Genomics 2008; 9:379. [PMID: 18691401 PMCID: PMC2547478 DOI: 10.1186/1471-2164-9-379] [Citation(s) in RCA: 49] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2007] [Accepted: 08/08/2008] [Indexed: 01/09/2023] Open
Abstract
BACKGROUND Microarray Comparative Genomic Hybridization (array CGH) provides a means to examine DNA copy number aberrations. Various platforms, brands and underlying technologies are available, facing the user with many choices regarding platform sensitivity and number, localization, and density distribution of probes. RESULTS We evaluate three different platforms presenting different nature and arrangement of the probes: The Agilent Human Genome CGH Microarray 44 k, the ROMA/NimbleGen Representational Oligonucleotide Microarray 82 k, and the Illumina Human-1 Genotyping 109 k BeadChip, with Agilent being gene oriented, ROMA/NimbleGen being genome oriented, and Illumina being genotyping oriented. We investigated copy number changes in 20 human breast tumor samples representing different gene expression subclasses, using a suite of graphical and statistical methods designed to work across platforms. Despite substantial differences in the composition and spatial distribution of probes, the comparison revealed high overall concordance. Notably however, some short amplifications and deletions of potential biological importance were not detected by all platforms. Both correlation and cluster analysis indicate a somewhat higher similarity between ROMA/NimbleGen and Illumina than between Agilent and the other two platforms. The programs developed for the analysis are available from http://www.ifi.uio.no/bioinf/Projects/. CONCLUSION We conclude that platforms based on different technology principles reveal similar aberration patterns, although we observed some unique amplification or deletion peaks at various locations, only detected by one of the platforms. The correct platform choice for a particular study is dependent on whether the appointed research intention is gene, genome, or genotype oriented.
Collapse
|
673
|
Ding X, Huang C, Sun H, Yang S, Ge R, Shen F, Wang Y. ZNF23 induces apoptosis in human ovarian cancer cells. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71463-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
674
|
Aaltonen T, Abulencia A, Adelman J, Akimoto T, Albrow MG, González BA, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Azzi-Bacchetta P, Azzurri P, Bacchetta N, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Baroiant S, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Bednar P, Behari S, Bellettini G, Bellinger J, Belloni A, Benjamin D, Beretvas A, Beringer J, Berry T, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bolshov A, Bortoletto D, Boudreau J, Boveia A, Brau B, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canelli F, Canepa A, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cooper B, Copic K, Cordelli M, Cortiana G, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lentdecker G, De Lorenzo G, Dell'orso M, Demortier L, Deng J, Deninno M, De Pedis D, Derwent PF, Di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Forrester S, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Gerberich H, Gerdes D, Giagu S, Giannetti P, Gibson K, Gimmell JL, Ginsburg C, Giokaris N, Giordani M, Giromini P, Giunta M, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein J, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Han JY, Handler R, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hauser J, Hays C, Heck M, Heijboer A, Heinemann B, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, Iyutin B, James E, Jayatilaka B, Jeans D, Jeon EJ, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Klute M, Knuteson B, Ko BR, Koay SA, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kraus J, Kreps M, Kroll J, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhlmann SE, Kuhr T, Kulkarni NP, Kusakabe Y, Kwang S, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, Lecompte T, Lee J, Lee J, Lee YJ, Lee SW, Lefèvre R, Leonardo N, Leone S, Levy S, Lewis JD, Lin C, Lin CS, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lu RS, Lucchesi D, Lueck J, Luci C, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Lytken E, Mack P, Macqueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin M, Martin V, Martínez M, Martínez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miles J, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello M, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Neu C, Neubauer MS, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oh SH, Oh YD, Oksuzian I, Okusawa T, Oldeman R, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pinera L, Pitts K, Plager C, Pondrom L, Portell X, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Reisert B, Rekovic V, Renton P, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Roy P, Ruiz A, Russ J, Rusu V, Saarikko H, Safonov A, Sakumoto WK, Salamanna G, Saltó O, Santi L, Sarkar S, Sartori L, Sato K, Savard P, Savoy-Navarro A, Scheidle T, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scott AL, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sfyrla A, Shalhout SZ, Shapiro MD, Shears T, Shepard PF, Sherman D, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soderberg M, Soha A, Somalwar S, Sorin V, Spalding J, Spinella F, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Stuart D, Suh JS, Sukhanov A, Sun H, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Tourneur S, Trischuk W, Tu Y, Turini N, Ukegawa F, Uozumi S, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Veszpremi V, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Würthwein F, Wagner P, Wagner RG, Wagner RL, Wagner J, Wagner W, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Wester WC, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wynne SM, Yagil A, Yamamoto K, Yamaoka J, Yamashita T, Yang C, Yang UK, Yang YC, Yao WM, Yeh GP, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zaw I, Zhang X, Zheng Y, Zucchelli S. Search for resonant tt[overline] production in pp[overline] collisions at sqrt[s]=1.96 TeV. PHYSICAL REVIEW LETTERS 2008; 100:231801. [PMID: 18643483 DOI: 10.1103/physrevlett.100.231801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2007] [Indexed: 05/26/2023]
Abstract
We report on a search for narrow-width particles decaying to a top and antitop quark pair. The data set used in the analysis corresponds to an integrated luminosity of 680 pb(-1) collected with the Collider Detector at Fermilab in run II. We present 95% confidence level upper limits on the cross section times branching ratio. Assuming a specific top-color-assisted technicolor production model, the leptophobic Z' with width Gamma(Z')=0.012M(Z'), we exclude the mass range M(Z')<725 GeV/c(2) at the 95% confidence level.
Collapse
|
675
|
Aaltonen T, Adelman J, Akimoto T, Albrow MG, Alvarez González B, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Aoki M, Apollinari G, Apresyan A, Arisawa T, Artikov A, Ashmanskas W, Attal A, Aurisano A, Azfar F, Azzi-Bacchetta P, Azzurri P, Bacchetta N, Badgett W, Barbaro-Galtieri A, Barnes VE, Barnett BA, Baroiant S, Bartsch V, Bauer G, Beauchemin PH, Bedeschi F, Bednar P, Behari S, Bellettini G, Bellinger J, Belloni A, Benjamin D, Beretvas A, Beringer J, Berry T, Bhatti A, Binkley M, Bisello D, Bizjak I, Blair RE, Blocker C, Blumenfeld B, Bocci A, Bodek A, Boisvert V, Bolla G, Bolshov A, Bortoletto D, Boudreau J, Boveia A, Brau B, Bridgeman A, Brigliadori L, Bromberg C, Brubaker E, Budagov J, Budd HS, Budd S, Burkett K, Busetto G, Bussey P, Buzatu A, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canelli F, Canepa A, Carlsmith D, Carosi R, Carrillo S, Carron S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavalli-Sforza M, Cerri A, Cerrito L, Chang SH, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho K, Chokheli D, Chou JP, Choudalakis G, Chuang SH, Chung K, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark A, Clark D, Compostella G, Convery ME, Conway J, Cooper B, Copic K, Cordelli M, Cortiana G, Crescioli F, Cuenca Almenar C, Cuevas J, Culbertson R, Cully JC, Dagenhart D, Datta M, Davies T, de Barbaro P, De Cecco S, Deisher A, De Lentdecker G, De Lorenzo G, Dell'Orso M, Demortier L, Deng J, Deninno M, De Pedis D, Derwent PF, Di Giovanni GP, Dionisi C, Di Ruzza B, Dittmann JR, D'Onofrio M, Donati S, Dong P, Donini J, Dorigo T, Dube S, Efron J, Erbacher R, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko WT, Feild RG, Feindt M, Fernandez JP, Ferrazza C, Field R, Flanagan G, Forrest R, Forrester S, Franklin M, Freeman JC, Furic I, Gallinaro M, Galyardt J, Garberson F, Garcia JE, Garfinkel AF, Genser K, Gerberich H, Gerdes D, Giagu S, Giakoumopolou V, Giannetti P, Gibson K, Gimmell JL, Ginsburg CM, Giokaris N, Giordani M, Giromini P, Giunta M, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Goulianos K, Gresele A, Grinstein S, Grosso-Pilcher C, Grundler U, Guimaraes da Costa J, Gunay-Unalan Z, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Han JY, Handler R, Happacher F, Hara K, Hare D, Hare M, Harper S, Harr RF, Harris RM, Hartz M, Hatakeyama K, Hauser J, Hays C, Heck M, Heijboer A, Heinemann B, Heinrich J, Henderson C, Herndon M, Heuser J, Hewamanage S, Hidas D, Hill CS, Hirschbuehl D, Hocker A, Hou S, Houlden M, Hsu SC, Huffman BT, Hughes RE, Husemann U, Huston J, Incandela J, Introzzi G, Iori M, Ivanov A, Iyutin B, James E, Jayatilaka B, Jeans D, Jeon EJ, Jindariani S, Johnson W, Jones M, Joo KK, Jun SY, Jung JE, Junk TR, Kamon T, Kar D, Karchin PE, Kato Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SB, Kim SH, Kim YK, Kimura N, Kirsch L, Klimenko S, Klute M, Knuteson B, Ko BR, Koay SA, Kondo K, Kong DJ, Konigsberg J, Korytov A, Kotwal AV, Kraus J, Kreps M, Kroll J, Krumnack N, Kruse M, Krutelyov V, Kubo T, Kuhlmann SE, Kuhr T, Kulkarni NP, Kusakabe Y, Kwang S, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster M, Lander RL, Lannon K, Lath A, Latino G, Lazzizzera I, LeCompte T, Lee J, Lee J, Lee YJ, Lee SW, Lefèvre R, Leonardo N, Leone S, Levy S, Lewis JD, Lin C, Lin CS, Linacre J, Lindgren M, Lipeles E, Lister A, Litvintsev DO, Liu T, Lockyer NS, Loginov A, Loreti M, Lovas L, Lu RS, Lucchesi D, Lueck J, Luci C, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Lytken E, Mack P, Macqueen D, Madrak R, Maeshima K, Makhoul K, Maki T, Maksimovic P, Malde S, Malik S, Manca G, Manousakis A, Margaroli F, Marino C, Marino CP, Martin A, Martin M, Martin V, Martínez M, Martínez-Ballarín R, Maruyama T, Mastrandrea P, Masubuchi T, Mattson ME, Mazzanti P, McFarland KS, McIntyre P, McNulty R, Mehta A, Mehtala P, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miles J, Miller R, Mills C, Milnik M, Mitra A, Mitselmakher G, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello M, Movilla Fernandez P, Mülmenstädt J, Mukherjee A, Muller T, Mumford R, Murat P, Mussini M, Nachtman J, Nagai Y, Nagano A, Naganoma J, Nakamura K, Nakano I, Napier A, Necula V, Neu C, Neubauer MS, Nielsen J, Nodulman L, Norman M, Norniella O, Nurse E, Oh SH, Oh YD, Oksuzian I, Okusawa T, Oldeman R, Orava R, Osterberg K, Pagan Griso S, Pagliarone C, Palencia E, Papadimitriou V, Papaikonomou A, Paramonov AA, Parks B, Pashapour S, Patrick J, Pauletta G, Paulini M, Paus C, Pellett DE, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pinera L, Pitts K, Plager C, Pondrom L, Portell X, Poukhov O, Pounder N, Prakoshyn F, Pronko A, Proudfoot J, Ptohos F, Punzi G, Pursley J, Rademacker J, Rahaman A, Ramakrishnan V, Ranjan N, Redondo I, Reisert B, Rekovic V, Renton P, Rescigno M, Richter S, Rimondi F, Ristori L, Robson A, Rodrigo T, Rogers E, Rolli S, Roser R, Rossi M, Rossin R, Rott C, Roy P, Ruiz A, Russ J, Rusu V, Saarikko H, Safonov A, Sakumoto WK, Salamanna G, Saltó O, Santi L, Sarkar S, Sartori L, Sato K, Savoy-Navarro A, Scheidle T, Schlabach P, Schmidt EE, Schmidt MA, Schmidt MP, Schmitt M, Schwarz T, Scodellaro L, Scott AL, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semenov A, Sexton-Kennedy L, Sfyrla A, Shalhout SZ, Shapiro MD, Shears T, Shepard PF, Sherman D, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Sinervo P, Sisakyan A, Slaughter AJ, Slaunwhite J, Sliwa K, Smith JR, Snider FD, Snihur R, Soderberg M, Soha A, Somalwar S, Sorin V, Spalding J, Spinella F, Spreitzer T, Squillacioti P, Stanitzki M, St Denis R, Stelzer B, Stelzer-Chilton O, Stentz D, Strologas J, Stuart D, Suh JS, Sukhanov A, Sun H, Suslov I, Suzuki T, Taffard A, Takashima R, Takeuchi Y, Tanaka R, Tecchio M, Teng PK, Terashi K, Thom J, Thompson AS, Thompson GA, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tokar S, Tollefson K, Tomura T, Tonelli D, Torre S, Torretta D, Tourneur S, Trischuk W, Tu Y, Turini N, Ukegawa F, Uozumi S, Vallecorsa S, van Remortel N, Varganov A, Vataga E, Vázquez F, Velev G, Vellidis C, Veszpremi V, Vidal M, Vidal R, Vila I, Vilar R, Vine T, Vogel M, Volobouev I, Volpi G, Würthwein F, Wagner P, Wagner RG, Wagner RL, Wagner-Kuhr J, Wagner W, Wakisaka T, Wallny R, Wang SM, Warburton A, Waters D, Weinberger M, Wester WC, Whitehouse B, Whiteson D, Wicklund AB, Wicklund E, Williams G, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfe C, Wright T, Wu X, Wynne SM, Yagil A, Yamamoto K, Yamaoka J, Yamashita T, Yang C, Yang UK, Yang YC, Yao WM, Yeh GP, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Yu SS, Yun JC, Zanello L, Zanetti A, Zaw I, Zhang X, Zheng Y, Zucchelli S. Search for the Higgs boson in events with missing transverse energy and b quark jets produced in pp collisions at square root(s)=1.96 TeV. PHYSICAL REVIEW LETTERS 2008; 100:211801. [PMID: 18518598 DOI: 10.1103/physrevlett.100.211801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/11/2008] [Indexed: 05/26/2023]
Abstract
We search for the standard model Higgs boson produced in association with an electroweak vector boson in events with no identified charged leptons, large imbalance in transverse momentum, and two jets where at least one contains a secondary vertex consistent with the decay of b hadrons. We use approximately 1 fb(-1) integrated luminosity of pp collisions at square root(s)=1.96 TeV recorded by the Collider Detector at Fermilab II experiment at the Tevatron. We find 268 (16) single (double) b-tagged candidate events, where 248+/-43 (14.4+/-2.7) are expected from standard model background processes. We observe no significant excess over the expected background and thus set 95% confidence level upper limits on the Higgs boson production cross section for several Higgs boson masses ranging from 110 to 140 GeV/c(2). For a mass of 115 GeV/c(2), the observed (expected) limit is 20.4 (14.2) times the standard model prediction.
Collapse
|